Novo Nordisk has unveiled promising topline Phase II results combining novel candidate cagrilintide with diabetes and obesity blockbuster treatment semaglutide, a two-in-one weekly therapy which could help it repel competition from Eli Lilly’s Mounjaro (tirzepatide).
The Phase II study of Novo Nordisk’s amylin analog cagrilintide with semaglutide – known as CagriSema – showed better lowering of blood sugar in type 2 diabetes patients compared with the